Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.

Yu Ha, Arcila ME, Rekhtman N, et al.: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-2247.
Piotrowska Z, Sequist L: Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J 2015;21,371-377.
Cross DA, Ashton SE, Ghiorghiu S,et al.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-1061.
Finlay MR, Anderton M, Ashton S, et al.: Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249-8267.
Jänne PA, Yang JC, Kim DW, et al.: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-1699.
Sequist LV, Soria JC, Goldman JW, et al.: Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-1709.
Park SJ, Kim HT, Lee DH, et al.: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556-560.
Ballard P, et al.: Preclinical activity of AZD9291 inEGFR-mutant NSCLC brain metastases J Thorac Oncol 2015;10(9, Suppl2): S300, abstract Mini 10.12.
Hata A, Katakami N, Yoshioka H, et al.: Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 2015;10:1553-1559.
Kuiper JL, Heideman DA, Thunnissen E, et al.: Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014;85:19-24.
Hata A, Katakami N, Yoshioka H, et al.: Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: Poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res 2015;35:1025-1031.
Ohashi K, Maruvka YE, Michor F, Pao E: Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-1080.
You do not currently have access to this content.